In a pact widely welcomed by investors, MorphoSys AG and Incyte Corp. have inked a global collaboration and license pact to further develop and commercialize MorphoSys's anti-CD19 antibody tafasitamab, formerly known as MOR208, which is in clinical development for the treatment of B-cell malignancies such as diffuse large B-cell lymphoma and chronic lymphocytic leukemia.
The alliance was announced on 13 January and provides MorphoSys a partner with considerable experience in hematology and oncology. Incyte in turn gets access to a novel compound that could help reduce reliance on its flagship JAK inhibitor, Jakafi (ruxolitinib)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?